Browse EX-10 agreements

Tyler Zeronda

33 Hall Rd

Chatham NJ 07928

Re:    Yarrow Bioscience, Inc. – Employment Offer

Dear Tyler,

Contingent upon the completion of the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization, dated as of December 17, 2025, and amended on January 30, 2026, by and among VYNE Therapeutics Inc., Yarrow Bioscience, Inc., and Yellow Merger Sub Corp. (the “Merger”), on behalf of VYNE Therapeutics, Inc. (to be renamed Yarrow Bioscience, Inc. following the Merger) (the “Company”), we are very pleased to offer you a position as Chief Financial Officer of the Company (“CFO”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below, to be effective as of, and contingent upon, the closing of the Merger (the “Effective Date”).

…

FIRST AMENDMENT TO LICENSE AGREEMENT

This FIRST AMENDMENT (the “First Amendment”) is made and entered into as of May 14, 2026 (“First Amendment Effective Date”), by and between BioAtla, Inc., a Delaware corporation (“BioAtla”), and Context Therapeutics Inc., a Delaware corporation (“Context”). Each of BioAtla and Context is sometimes referred to individually in this First Amendment as a “Party” and collectively as the “Parties.”

WHEREAS, BioAtla and Context are parties to that certain License Agreement, dated September 23, 2024 (the “Agreement”);

…

Exhibit 10.5

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL

REMUNERATED PRIVATE INVESTMENT AGREEMENT

In Madrid, Spain on March 30th, 2026.

PARTIES

On the one hand

Mr. Rafael Jesús Contreras Chamorro with ID NUM. [***], acting in the name and on behalf of the company NOMADAR CORP, with TAX ID EIN: 99-3383359, domiciled for these purposes in United States, in the State of Texas is 5015 Hwy 59 N, Marshall, 75670.

And, on the other hand

…

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL

REMUNERATED PRIVATE INVESTMENT AGREEMENT

In Madrid, Spain on March 4th, 2026.

PARTIES

On the one hand

Mr. Rafael Jesús Contreras Chamorro with ID NUM. [***], acting in the name and on behalf of the company NOMADAR CORP, with TAX ID EIN: 99-3383359, domiciled for these purposes in United States, in the State of Texas is 5015 Hwy 59 N, Marshall, 75670.

And, on the other hand

…

​

ACKNOWLEDGMENT AND FOURTH AMENDMENT TO

AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT

This ACKNOWLEDGMENT AND FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (this “Amendment”), dated as of March 27, 2026, is entered into by and among XBP Americas, LLC (formerly known as Exela Technologies BPA, LLC,) a Delaware limited liability company (the “Borrower”), brf finance co. llc, a Delaware limited liability company, as administrative agent (the “Agent”), and the financial institutions party to the Credit Agreement referred to below as a “Lender; and is acknowledged by the guarantors party to such Credit Agreement (the “Guarantors”).

RECITALS

…

​

THIRD AMENDMENT TO FINANCING AGREEMENT

This THIRD AMENDMENT TO FINANCING AGREEMENT, dated as of March 27, 2026 (this “Amendment”), by and among XBP Americas, LLC, a Delaware limited liability company (f/k/a Exela Technologies BPA, LLC) (the “Lead Borrower” and “Administrative Borrower”) on behalf of the Borrowers (as defined below) and Ankura Trust Company, LLC, a New Hampshire limited liability company (“Ankura”), as collateral agent for the Secured Parties (in such capacity, together with its successors and assigns in such capacity, the “Collateral Agent”), and Ankura, as administrative agent for the Lenders (in such capacity, together with its successors and assigns in such capacity, the “Administrative Agent” and together with the Collateral Agent, each an “Agent” and collectively, the “Agents”) which amends that certain Financing Agreement, dated as of July 29, 2025 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, including as amended by that certain First Amendment to Financing Agreement, dated as of January 21, 2026 and by

…

​

FOURTH AMENDMENT TO

CREDIT AND SECURITY AGREEMENT

This FOURTH AMENDMENT TO CREDIT AND SECURITY AGREEMENT (this “Amendment”), dated as of March 27, 2026, is entered into by and among XBP Americas, LLC (formerly known as Exela Technologies BPA, LLC) a Delaware limited liability company, (the “Borrower”), the guarantors party thereto (the “Guarantors”), MIDCAP FUNDING IV TRUST, a Delaware statutory trust, as administrative agent (the “Agent”), and the financial institutions or other entities from time to time parties hereto, each as a Lender.

RECITALS

…

[Certain information has been excluded because it both (i) is not material and (ii) is the type the Company treats as private or confidential]

NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

…

FIRST AMENDMENT TO COLLABORATION AGREEMENT

This First Amendment to the Collaboration Agreement (this "First Amendment") is entered into as of January 13, 2026 by and between Rani Therapeutics, LLC, a California limited liability company ("Rani"), and ProGen Co., Ltd. ("ProGen"). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Agreement.

Recitals

WHEREAS, Rani and ProGen are parties to that certain Collaboration Agreement dated June 17, 2024 (the "Agreement");

WHEREAS, pursuant to Section 10.5.3 (Non-Program Data) of the Agreement, ProGen has the right to publicly disclose, publish and/or present Compound-Specific Data without requiring prior consent of Rani;

WHEREAS, Rani and ProGen wish to amend Section 10.5.3 (Non-Program Data) of the Agreement to coordinate the disclosure of certain Compound-Specific Data with the disclosure of Program Data, and leave all other terms unchanged;

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, the parties hereby agree as follows:

…

RANI THERAPEUTICS HOLDINGS, INC.

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

(AS AMENDED EFFECTIVE MARCH 18, 2026)

Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Rani Therapeutics Holdings, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board service upon and following the date of the underwriting agreement between the Company and the underwriters managing the initial public offering of the Company’s Class A common stock (the “Common Stock”), pursuant to which the Common Stock is priced in such initial public offering (the “Effective Date”). An Eligible Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash may be paid or equity awards are to be granted, as the case may be. This policy is effective as of the Effective Date and may be amended at any time in the sole discretion of the Board or the Compensation

…

Exhibit 10.17

[*] Certain information in this document has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential.

MASTER SERVICES AGREEMENT

This Master Services Agreement (the “MSA”) is made on 31 March 2026 (the “Effective Date”)

Between:

1.	SAI AU NO.2 PTY LTD, a company incorporated in Australia (ACN: 695 331 063), having its registered office at U 303 44 Miller St, North Sydney NEW SOUTH WALES, Australia (“Service Provider”);

and

2.	SPOCHUB SOLUTIONS PRIVATE LIMITED, a company incorporated under the Companies Act 2013, having Corporate Identification No. U72900MH2021PTC355918 and having Legal Entity Identifier (LEI) Code 335800RYBFDD8JCN9Y10, and its registered office at P.No. B-24/25, NICE Area, MIDC, Satpur, Nashik, Maharashtra, India – 422 007 (“First Customer”);

…

EXECUTION VERSION

SECOND AMENDMENT AGREEMENT

This Second Amendment Agreement (“Agreement”), dated as of May 13, 2026, is made by and among JGB Capital L.P., JGB Partners L.P. and JGB (Cayman) Gasconne Ltd. (collectively, the “Purchasers” and each a “Purchaser”), Marpai Inc., a Delaware corporation (the “Company”), JGB Collateral LLC, a Delaware limited liability company (the “Agent”), as agent for the Purchasers, and each Person executing this Agreement as a guarantor, pledgor and/or mortgagor (collectively, the “Credit Support Parties”).

…